10:07 AM EDT, 05/07/2026 (MT Newswires) -- Harmony Biosciences (HRMY) shares fell over 6% in Thursday trading after the company's Q1 earnings and revenue fell short of analysts'consensus.

The company reported Q1 earnings of $0.55 per diluted share, down from $0.78 a year earlier.

Analysts polled by FactSet expected $0.69.

Net product revenue for the quarter ended March 31 was $215.4 million, up from $184.7 million a year earlier.

Analysts expected revenue of $220.8 million.

As of March 31, the company said it had $870.5 million in cash, cash equivalents, and investments.

The company reiterated its 2026 WAKIX net revenue guidance of $1 billion to $1.04 billion. Analysts expect $1.01 billion.

Price: 29.52, Change: -3.26, Percent Change: -9.95